SUMM Summit Therapeutics

Exercise of Restricted Stock Units

Exercise of Restricted Stock Units

Summit Therapeutics plc 

(‘Summit’ or the ‘Company’)

Exercise of Restricted Stock Units

Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that following the exercise of restricted stock units by former directors, the Company has issued 269,230 new ordinary shares of one penny each (the “New Ordinary Shares”).

Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company’s existing ordinary shares, and admission is expected to occur on or around 30 January 2020.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 336,159,511. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, Enterobacteriaceae and N. gonorrhoeae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit and follow us on Twitter @summitplc.

Contacts

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) 
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti  

-END-

EN
27/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Summit Therapeutics

 PRESS RELEASE

AIM Delisting Reminder

AIM Delisting Reminder Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”) will cease to be admitted to trading on AIM at 7.00 am on 24 February 2020. Accordingly, the final day of trading on AIM of the Company’s Ordinary Shares will be 21 February 2020. The Company’s ...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207 ordinary shares by Maky Zanganeh and Associates, Inc. (“MZA”). The Company has a con...

 PRESS RELEASE

Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eur...

Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK, and Cambridge, MA, US, 6 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The $1.0 milli...

 PRESS RELEASE

Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conferen...

Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference on 10 February 2020 at 2:15pm EST in New York City. A live webcast of the presentation will be available in the Investors section of the Company's website, . A replay ...

 PRESS RELEASE

Exercise of Restricted Stock Units

Exercise of Restricted Stock Units Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that following the exercise of restricted stock units by former directors, the Company has issued 269,230 new ordinary shares of one penny each (the “New Ordinary Shares”). Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company’s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch